The link between CHIP-associated pathomechanisms and inflammatory cytokines is of particular interest since anti-inflammatory therapy with the monoclonal antibody canakinumab targeting IL-1β has recently been shown to significantly lower the rate of recurrent cardiovascular events compared to placebo in a large randomized, double-blind trial involving 10,061 patients with previous myocardial infarction and a C-reactive protein (CRP) level of ≥2 mg/L. This evidence concerns the gene CRP and myocardial infarction.